Below the Surface: Targeting Corneal Nerves in the Treatment of Ocular Conditions (CME Monograph)
Corneal nerve dysfunction is the underlying cause of neurotrophic keratitis and has an etiologic role in the pathogenesis of dry eye disease and its symptoms. Knowledge of the mechanisms has implications for establishing a diagnosis in patients with ocular surface disease and using neuroregenerative therapy. This educational activity is based on the proceedings of a live CME symposium that took place on Saturday, October 1, 2022. The desired results of this activity are to increase understanding of the role of the corneal nerve in ocular surface health and disease as a foundation for enabling proper diagnosis and for selecting optimal treatment.
This educational activity is intended for ophthalmologists.
After completing this activity, participants will be better able to:
- Review the role of corneal nerves in maintaining ocular surface homeostasis
- Review the neurosensory etiologies of ocular surface diseases
- Review strategies for diagnosing diseases related to corneal nerve dysfunction
- Select optimal treatment strategies for patients with diseases related to corneal nerve dysfunction
|Preeya K. Gupta, MD (Chair)|
Triangle Eye Consultants
Raleigh, North Carolina
Adjunct Associate Professor of Ophthalmology
Cornea, Cataract, & Refractive Surgery
New Orleans, Louisiana
|Pedram Hamrah, MD|
Professor of Ophthalmology, Neuroscience, and Immunology
Co-Director, Cornea Service
Department of Ophthalmology
Tufts Medical Center
Tufts University School of Medicine
|Melissa Toyos, MD|
Partner and Director of Research
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Preeya K. Gupta, MD, is a consultant for Alcon, Aldeyra Therapeutics, Allergan, Azura Ophthalmics Ltd, Expert Opinion MD, Hanall Biopharma, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, New World Medical, Inc, Novartis Pharmaceuticals Corporation, Ocular Science, Oyster Point Pharma, Inc, Sight Sciences, Sun Pharmaceutical Industries, Inc, Surface Pharmaceuticals Inc, TearClear, TearLab Corporation, TissueTech, Inc, Visionology, and Zeiss.
Pedram Hamrah, MD, is a consultant for Amber Ophthalmics, Brill Pharma, Dompé US, Inc, Eyenovia, Inc, Kala Pharmaceuticals, Novaliq GmbH, Santen Inc, and Xequel Bio; is an advisory board member of Dompé US, Inc, Hawkeye Therapeutics, Novartis Pharmaceuticals Corporation, Noveome Biotherapeutics, Inc, and Oyster Point Pharma, Inc; and is a contracted researcher for Claris Biotherapeutics*, CooperVision, Dompé US, Inc, Novartis Pharmaceuticals Corporation, Noveome Biotherapeutics, Inc, Ocular Therapeutix, Inc, OKYO Pharma, Limited, and Oyster Point Pharma, Inc*.
Melissa Toyos, MD, is a consultant for Bausch & Lomb Incorporated, Dompé US, Inc, Mallinckrodt, Oyster Point Pharma, Inc, Recordati Rare Diseases, RVL Pharmaceuticals, Inc, Santen Inc, and Sun Pharmaceutical Industries, Inc; is a contracted researcher for Allysta Pharmaceuticals, Inc, Amber Ophthalmics, Bausch & Lomb Incorporated, Dompé US, Inc, Glaukos Corporation, GreenLight Clinical, Kala Pharmaceuticals, Lumenis Be Ltd, Novartis Pharmaceuticals Corporation, Rayner, Recordati Rare Diseases, Santen Inc, and Sun Pharmaceutical Industries, Inc; and is on the speakers bureau for Bausch & Lomb Incorporated, Mallinckrodt, Recordati Rare Diseases, and RVL Pharmaceuticals, Inc.
* The financial relationship existed during the past 24 months but has now ended.
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Dompé US, Inc.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at firstname.lastname@example.org.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC, Dompé US, Inc, EyeNet, or the American Academy of Ophthalmology.
©2023 MedEdicus LLC. 281.2
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation